Venkat Nelabhotla

@VyomeInc $HIND expands into one of the largest opportunities in immunology through a highly capital efficient licensing deal with Impetis Biosciences, a @TataCompanies entity. Selective JAK inhibitor assets targeting a potential ~$57B TAM. No upfront payments. No development milestones. Royalty only post commercialization. Future development planned through non dilutive pathways while maintaining sharp focus on VT1953. Scientific depth. Capital discipline. Global innovation corridors. #Biotech #Immunology #NASDAQ #Innovation

@VyomeInc $HIND expands into one of the largest opportunities in immunology through a highly capital efficient licensing deal with Impetis Biosciences, a @TataCompanies entity. Selective JAK inhibitor assets targeting a potential ~$57B TAM. No upfront payments. No development milestones. Royalty only post commercialization. Future development planned through non dilutive pathways while maintaining sharp focus on VT1953. Scientific depth. Capital discipline. Global innovation corridors. #Biotech #Immunology #NASDAQ #Innovation

Dr. Charles Tilley, PhD, RN, CWOCN — an experienced wound and palliative care specialist who has cared for malignant fungating wound patients firsthand… highlights with an independent perspectives on the severe burden of persistent malodor and pain, and the impact these symptoms can have on dignity and emotional well-being. He also highlights that there are currently no FDA-approved therapies specifically for treating these symptoms. At @VyomeInc $HIND we are advancing VT-1953, our Phase 2 completed investigational candidate, into the next stage of development. Independent analysts have sized a potential US TAM of $2.2B Respect to the physicians and caregivers supporting these patients every day. #Biotech #Oncology #CancerCare #NASDAQ

Biotech is reopening in 2026. But the playbook has changed. Q1 tells the story: $1.7–1.8B IPOs (best since 2021) $10B+ follow-ons (~3x YoY) ~70%+ jump in total financings Capital is back. But it’s not chasing stories. It’s rewarding: Clean cap tables Tight cost discipline Smart, fast clinical design Real regulatory clarity This is not the hype cycle. It’s the execution cycle. For public biotech: Clarity drives valuation. Discipline sustains it. The next winners won’t be the loudest. They’ll be the most predictable. #Biotech2026 #BiotechInvesting #CapitalMarkets #HealthcareInnovation

The Economic Survey sets a thoughtful direction by recognizing growth as multi-dimensional, not just economic, but social, human, technological, and institutional. It provides a strong foundation and clear intent. Continued focus on these dimensions will help translate vision into sustained outcomes as we move toward Viksit Bharat 2047. Wishing you strength and success in advancing this important journey.

The Economic Survey 2025-26 was tabled in the Parliament today, giving an economic overview of the past year and ideas for the road ahead. In a world defined by geopolitical fragmentation and economic turbulence, India stands as a global bright spot - resilient, stable, and surging forward. • The Survey mentions that amidst global uncertainties, the Indian economy has maintained robust momentum, with the First Advance Estimates placing real GDP growth at 7.4% for FY 2025-26. This performance reaffirms India's status as the fastest-growing major economy for the fourth consecutive year. • Under the leadership of Hon’ble PM Shri @narendramodi, our macroeconomic fundamentals are stronger than ever. We have successfully navigated global headwinds to place India on a high-growth trajectory, improving our potential GDP growth to 7%. • Read the Economic Survey here: indiabudget.gov.in/economicsurvey… (1/n) 

From lost in translation to found in connection, Google didn’t just translate words, it quietly translated worlds. In the next twenty years, maybe the real question is not how well we translate, but how well we act on that understanding. Because words can connect us, but it is our actions that truly complete the meaning.

Hello. How are you? Thank you. I love you. Please. Some of the most frequently translated phrases of the past 20 years! Google Translate began twenty years ago with a mission to help people understand one another, regardless of the language they speak. What started as a small experiment has become a global tool that helps over 1 billion users every month. In that time Translate has evolved from simple pattern matching to true understanding. In 2006, it relied on statistical machine learning to look for patterns in small word clusters. By 2016, we pioneered a shift to neural networks to move beyond literal word-for-word translations, and today we’re using our powerful Gemini models to make Translate even more helpful. We are moving from text to fluid, real-time conversations. With our latest models, you can even use your headphones as a personal interpreter that preserves your original tone and cadence - it’s an amazing experience! One of the interesting things about AI is that as we make progress, we begin to take it for granted. If you met a person who could translate across a hundred languages faster than any human can, you would be so impressed. Today, one product does that for nearly 250 languages, and we kind of just shrug. Being able to say thank you in 250 languages is not something I take for granted. So to the 1 billion who use Google Translate - merci, dhanyavaad, arigatō, gracias, and thank you! Let’s see what the next 20 years will bring.

Real breakthroughs don’t come from noise… they come from execution. We shared Phase 2 data at prestigious AACR this week from our work at @VyomeInc $HIND Malignant fungating wounds remain one of the toughest conditions in advanced cancer…impacting dignity, daily life, with no FDA-approved therapies. Large unmet need, multi-billion TAM. And we’re building beyond that.. Stay focused. Execute well. One step at a time. #Biotech #Oncology #LifeSciences

FDA’s approach to rare diseases with no approved treatments represents a distinct regulatory pathway that many may find worth understanding. When unmet medical need is significant… the benefit-risk calculus shifts… FILSPARI… $TVTX… IgA Nephropathy… no prior approved therapy… accelerated approval 2023… full approval 2024… Being first in an indication with genuine unmet need in a rare disease creates a durable clinical and commercial position. This dynamic appears to remain underappreciated in how rare disease assets are valued… $TVTX $XBI #RareDisease #Biotech #FDAApproval @VyomeInc

Biotech IPO window… opening well in 2026. Eikon ~$381M, Generate ~$400M, Kailera ~$300M+… big raises… Smart money is back… but only for data, discipline, and differentiation. This cycle… not hype to spike, but price right to grow.. #Biotech #IPO #CapitalMarkets #Healthcare #Investing #PublicMarkets

Immuno-inflammation and rare diseases is no longer a chapter… it’s the headline. The $5.6B Biogen/Apellis deal says it loud… when science clicks, capital ticks… what was once niche is now signal-rich and sizzling. A shift many in the space, including teams like @VyomeInc $HIND are closely tracking. Not hype, but hypothesis turning into hope… not noise, but data finding its voice. #Immunology #RareDiseases #Biotech #DrugDiscovery

After a brief pause… here’s the progress of @VyomeInc (@Nasdaq $HIND) 2025 → 2026 2025 = foundation 2026 = execution No hype. Just setup → Delivery • clear driver: VT-1953 - Treating malodor of Maligant Fungating Wounds • Pivotal study path → FDA interaction in Q2 2026 • Targeting a large unmet need with zero approved therapies • ~$2.2B U.S. rare diseases opportunity • ~$1B+ potential post-Phase 3 • Clean cap table • Disciplined capital strategy • Runway through key inflection points (mid-2027) No noise. Just alignment + execution In a market full of dilution stories, we’re building differently and we are very dilution conscious. No overstatements. Just a company getting ready for its breakout phase. Grateful to everyone backing this journey. #Biotech #ExecutionMatters #CapitalDiscipline

When cure is no longer possible, care becomes everything. Comfort, dignity, presence… these aren’t extras. They shape how families grieve, how communities heal, and how society remembers what it means to be human. #TerminalCancer #EndOfLifeCare #HumanDignity #QualityOfLife #Oncology @VyomeInc

The biotech reset is real. As highlighted in Clinical Research News, public biopharma is increasingly focused on capital discipline, milestone-driven development, and smarter execution. The message is clear: long-term value is built through focus and execution. #Biotech #ExecutionMatters #CapitalDiscipline #LifeSciences

@BioCentury This is why Phase 2 exists… to learn and optimize. Dose selection, especially for monthly GLP-1s, is critical to balancing efficacy and tolerability. Phase 3 is about getting that balance right. Wishing them success as they move forward.

Pfizer's once-monthly #GLP1 data come in lower than expected, 12.3% placebo-adjusted weight loss at 28 wks, pushing the pharma to pursue a higher once-monthly dose in Ph III #obesity testing $PFE $LLY $NVO buff.ly/CuDwQAW

This is straight out of the old BCG playbook, but at a hyperscale. One mega cash cow funds a whole constellation of Stars, with patience to let the Question Marks mature. The winners won’t just have blockbusters… they’ll have capital discipline to keep reinvesting while others tap out.

Back on my beat, I'm watching $LLY rack up another big round of $$ wins around its obesity drug. This is the model for Big Pharma now. Get the ginormous cash cow solidly in place and beef up the pipeline to find more blockbusters. "Little" markets will be shunned. Life will be good -- for quite some time. Easier said than done, of course. endpoints.news/lilly-beats-sa…

@Sanctuary_Bio Biotech’s “quiet” in 2026 feels like conviction, not complacency. While noise trades swing wildly, science and execution are steadily rebuilding value. This is how durable cycles start… calmly, then decisively.

what a strange year so far. Biotech seems like a safe haven in comparison where as other stuff making crazy moves. I like the peace and quiet personally. Took a small hit on GUTS but I can't complain about 3.25% ytd a bit after a month into the year. That will still work

@avidresearch Cash-pay GLP-1s are rewriting the access playbook… lower margins, massive reach, and real-world adoption finally scale together. When volume + outcomes align, leaders don’t just win share… they define the market and create categories.

Zepbound cash pay Wegovy pill cash pay. Both will make good $ (lower margins made up by volume) $NVO cheap IMO (Wegovy pill trajectory is impressive). $LLY orforglipron just not as effective and IMO, Zepbound and Wegovy will dominate.

A big win for rare disease innovation. PRVs don’t just speed reviews.. they unlock capital, de-risk science, and pull life-saving therapies forward for children who can’t wait. This is policy done right. #RareDisease #BiotechInnovation #PatientsFirst #PolicyMatters